51934-38-4

Usage

Uses

Used in Pharmaceutical Industry:
6-bromonaphthalene-1-carboxylic acid is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications.
Used in Chemical Reactions:
6-bromonaphthalene-1-carboxylic acid is used as a reagent in various chemical reactions, facilitating the synthesis of other organic compounds. Its presence can influence the reaction pathways and outcomes, making it a valuable component in the development of new chemical products.
Used in Research and Development:
6-bromonaphthalene-1-carboxylic acid is used as a research compound to study its biological effects and environmental fate. More research is needed to fully understand its potential applications and implications in various fields, such as medicine, agriculture, and environmental science.

Upstream product

• 24050-49-5 3-bromonaphthalic-1,8-anhydride 
• 91065-16-6 6-bromo-1-cyanonaphthalene 
• 67878-76-6 5-bromo-2-naphthalenecarboxylic acid methyl ester 
• 91135-41-0 5-Cyan-naphthylamin-⁽²⁾ 
• 177846-05-8 6-bromo-1,2-dihydronaphthalene-1-carboxylic acid 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 81-84-5 1,8-Naphthalic anhydride 
• 91804-23-8 5-cyanonaphthalene-2-carboxylic acid methyl ester 
• 94629-28-4 5-Cyan-naphthoesaeure-⁽²⁾-azid 
• 91493-88-8 5-Cyan-naphthoesaeure-⁽²⁾-hydrazid 

Downstream Products

• 86456-56-6 6-bromo-1-naphthaldehyde 
• 33626-98-1 methyl 6-bromo-2-naphthoate 
• 91804-22-7 6-Cyan-naphthoesaeure-(1)-methylester 

Relevant academic research and scientific papers

Concise Synthesis of Natural Phenylphenalenone Phytoalexins and a Regioisomer

Concise total syntheses of the natural phytoalexins 2-hydroxy-8-(4-hydroxyphenyl)phenalen-1-one (1), 2-hydroxy-8-(3,4-dihydroxyphenyl)phenalen-1-one (2), and hydroxyanigorufone (4), together with regioisomer 3 are accomplished in 11 or 12 steps. The synthetic strategy features a Friedel-Crafts acylation to construct the 1H-phenalen-1-one tricyclic core followed by a Suzuki cross-coupling to obtain the target compounds.

NOVEL EP2 RECEPTOR AGONISTS

The compounds of formula (1), in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

A rapid, large-scale synthesis of a potent cholecystokinin (CCK) 1R receptor agonist

The development of a scalable synthesis of a potent cholecystokinin (CCK) IR receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support

Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17

Two novel classes of non-steroidal substrate mimetics were synthesised and examined for their potency as inhibitors of human CYP17. Selected compounds were tested for inhibition of hepatic CYP enzymes 3A4, 1A2, 2C9 and 2C19. The most promising compound 15

The mercury-mediated decarboxylation (Pesci reaction) of naphthoic anhydrides investigated by microwave synthesis

The mercury-mediated decarboxylation (Pesci reaction) of several substituted naphthoic anhydrides has been investigated by microwave synthesis. A laboratory microwave reactor was found to be ideal for small-scale preparations of this slow reaction, reducing reaction times from typically four days to less than 1 h for the three-step process. The ionic reaction medium rapidly heated to high temperatures under microwave heating and could be efficiently maintained by low microwave power settings. Generation of stoichiometric CO2 was safely contained within the reaction tubes. A simplified reaction procedure has been developed. For substituted naphthoic anhydrides, 1H NMR analysis of the naphthoate ester derivatives indicated no change in the regioisomer ratio compared to previously reported thermal values.

A new approach to rapid parallel development of four neurokinin antagonists. Part 2. Synthesis of ZD6021 cyano acid

The manufacture of ZD6021 cyano acid (1) using a new project approach is described. Research Department processes were scaled up to 100 L if process safety anal robustness were not compromised; other factors were treated according to the new approach. By using this strategy, we were able to manufacture a key intermediate on sufficient scale to support delivery of 1 kg quantities of bulk drug within 6 months of the start of lab work.

Discovery of novel, orally active dual NK1/NK2 antagonists

Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.

Preparation of a series of substituted fluoromethylnaphthalenes

A series of 22 3- and 4-substituted 1-fluoromethylnaphthalenes have been synthesized.Details of practical procedures for the preparation of all intermediates are described, and physical properties for all of the substituted naphthalenes synthesized, and spectral parameters for 51 previously unknown compounds, are given.